Active — Not RecruitingNot Applicable

Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD

Austria847 participantsStarted 2022-09-12

Plain-language summary

This observational prospective study aims to evaluate the LDL-C change and adherence to inclisiran in combination with other lipid lowering therapies or lipid lowering treatments (LLTs) under conditions of routine clinical practice.

Who can participate

Age range18 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Participants who are 18 years or older
✓. Participants with hypercholesterolemia having a diagnosis of ASCVD, ASCVD RE or HeFH
✓. Participants who are not at LDL-C goal as per their CV risk according to respective clinical guidelines
✓. Participants who per physician's criteria need to optimize their LLT
✓. Participants who provide written informed consent to participate in the study
✓. Participants who initiate inclisiran under conditions per local label and have LDL-C values available at baseline or within 3 months before treatment initiation.

Exclusion criteria

✕. Participants that have received inclisiran previously
✕. Participants participating in a clinical trial with investigational product 3 Participants switching from previous PCSK9 mab treatment (within 90 days prior to Index date)

What they're measuring

Percentage change in LDL-C from baseline to 10 months

Timeframe: Baseline, 10 months

Trial details

NCT IDNCT05399992

SponsorNovartis Pharmaceuticals

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2026-10-05

View on ClinicalTrials.gov More Primary Hypercholesterolemia trials